Neurocrine Biosciences Shares Jump After Raising Ingrezza Sales Guidance
- Tucked in its Q2 earning release, Neurocrine Biosciences Inc said that in August, the Phase 2a study of NBI-827104 in essential tremor did not meet specified endpoints.
- Based on the totality of data from the Phase 2a study, at this time, the company will not proceed further with the clinical development of NBI-827104 in essential tremors.
- The FDA has signed off Neurocrine's Investigational New Drug (IND) Application for a Phase 2 trial of NBI-1117568 for schizophrenia.
- The achievement triggers a $30 million payment to Neurocrine's partner Sosei Heptares.
- NBI-1117568 is an oral, selective muscarinic M4 receptor agonist in development for treating schizophrenia and other neuropsychiatric disorders.
- Clinical studies completed to date have shown NBI-1117568 to be generally well tolerated.
- Q2 sales increased 31% Y/Y to $378.2 million, and Ingrezza product sales were $350 million, with total prescriptions of approximately 64,200.
- Net product sales and TRx grew 32% and 31%, respectively, vs. the second quarter of 2021.
- The company raised the FY22 Ingrezza sales outlook to $1.35 billion - $1.4 billion, higher than the $1.25 billion - $1.35 billion expected earlier.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.